Ocugen and Bharat Biotech Announce Execution of Definitive Agreement for the Commercialization of Covaxin in the US Market

Home / News / Ocugen and Bharat Biotech Announce Execution of Definitive Agreement for the Commercialization of Covaxin in the US Market


https://eyewire.news/articles/ocugen-and-bharat-biotech-announce-execution-of-definitive-agreement-for-the-commercialization-of-covaxin-in-the-us-market/



            
                
                                            Recent NewsExperts happy with India Covaxin efficacy results
Covaxin: Bharat Biotech submits interim phase 3 results to drugs regulator
British Medical Journal Raises Concerns Over Integrity of mRNA Molecules Used in COVID-19 Vaccines After Leaked Documents Raises Questions
Denmark, Norway, Iceland halt use of AstraZeneca vaccine over concerns of blood clots
J & J’s next COVID-19 vaccine challenge? Hurdling the ‘66%’ perception to win over a vaccine-hesitant public
			
	
		
	



	
		About Us
	
	
		
	



	
		In 1993, Biogenetech started with just 10 staff, distributing diagnostic kits and nuclear medicines.

In the past 25 years, Biogenetech introduced more than 15 innovative vaccines and pharmaceuticals, contributing to the improvements in public health standards in Thailand, protecting our population from numerous infectious diseases!

	



	
	Read More


        

        
                    
                
                    Related Health Education
                                        
                        
                            
                                
                                    Covaxin: Bharat Biotech submits interim phase 3 results to drugs regulator                                
                            
                        
                                        
                        
                            
                                
                                    British Medical Journal Raises Concerns Over Integrity of mRNA Molecules Used in COVID-19 Vaccines After Leaked Documents Raises Questions                                
                            
                        
                                        
                        
                            
                                
                                    Denmark, Norway, Iceland halt use of AstraZeneca vaccine over concerns of blood clots                                
                            
                        
                                        
                        
                            
                                
                                    J & J’s next COVID-19 vaccine challenge? Hurdling the ‘66%’ perception to win over a vaccine-hesitant public                                
                            
                        
                                        
                        
                            
                                
                                    How can Johnson & Johnson and AstraZeneca fight vaccine misperceptions? Try straight talk

Related Posts

Ocugen and Bharat Biotech Announce Execution of Definitive Agreement for the Commercialization of Covaxin in the US Market

Related Health Education